Leukopaks are highly-enriched leukapheresis-derived products obtained from an IRB-approved collection facility. Leukopaks contain higher concentrations of mononuclear cells, B cells, T cells, stem/progenitor cells, dendritic cells, and other cell types as compared to standard venipuncture collection methods or buffy coat products. Healthy, consented donors undergo a medical screening evaluation and are administered a single 240ug/kg TBW dose of Mozobil (plerixafor) per IRB approved protocols prior to Leukapheresis. Leukapheresis is performed using the Spectra Optia® Apheresis System with healthy, consented donors following IRB-approved protocols. MNC rich cells are continuously collected from 2-2.5 donor blood volumes into a sterile bag using ACD-A as an anticoagulant. Approximately 120mL of autologous plasma is automatically collected directly into the cell pool following leukapheresis. After a sample is withdrawn for quality testing, a nominal volume of 290mL is transferred into a sterile transfer bag prior to shipping. The total nucleated cell count is determined using AO/PI from the collection and provided as information. Cell counts and CD34 quantities will vary based on the donor's response to mobilization. Mozobil mobilization efficiency can vary from 4-54 CD34+ cells/ul peripheral blood (50-648 M CD34+cells/12L BV collection). The total nucleated cell count is determined using AO/PI from the combined pool and provided as information. Fresh Mobilized leukapheresis products typically contain up to 0.5% CD34+ cells, 40% granulocytes, and 5% hematocrit. Exact percentages will vary from donor to donor.
English
Deutsch
